Mild Renal Dysfunction and Metabolites Tied to Low HDL Cholesterol Are Associated With Monocytosis and Atherosclerosis
暂无分享,去创建一个
Thomas J. Wang | O. Melander | B. Hedblad | R. Gerszten | A. Tall | G. Engström | M. Magnusson | L. Yvan-Charvet | Ding Ai | A. Ganda
[1] Bill Bynum,et al. Lancet , 2015, The Lancet.
[2] Thomas J. Wang,et al. A diabetes-predictive amino acid score and future cardiovascular disease. , 2013, European heart journal.
[3] John Spertus,et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study , 2012, The Lancet.
[4] R. Vasan,et al. Metabolite Profiling Identifies Pathways Associated With Metabolic Risk in Humans , 2012, Circulation.
[5] D. Panagiotakos,et al. Association between serum cystatin C, monocytes and other inflammatory markers , 2012, Internal medicine journal.
[6] O. Melander,et al. Incidence of Coronary Events and Case Fatality Rate in Relation to Blood Lymphocyte and Neutrophil Counts , 2012, Arteriosclerosis, thrombosis, and vascular biology.
[7] B. Chaitman,et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. , 2011, The New England journal of medicine.
[8] A. Hirayama,et al. Serum cystatin C is associated with early stage coronary atherosclerotic plaque morphology on multidetector computed tomography. , 2011, Atherosclerosis.
[9] Josef Coresh,et al. Expressing the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) cystatin C equations for estimating GFR with standardized serum cystatin C values. , 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[10] D. Herrington,et al. The Association of Chronic Kidney Disease and Metabolic Syndrome with Incident Cardiovascular Events: Multiethnic Study of Atherosclerosis , 2011, Cardiology research and practice.
[11] M. Landray,et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial , 2011, The Lancet.
[12] Y. Marcel,et al. Autophagy regulates cholesterol efflux from macrophage foam cells via lysosomal acid lipase. , 2011, Cell metabolism.
[13] Robert P Light,et al. Patterns and prognostic value of total and differential leukocyte count in chronic kidney disease. , 2011, Clinical journal of the American Society of Nephrology : CJASN.
[14] V. Mootha,et al. Metabolite profiles and the risk of developing diabetes , 2011, Nature Medicine.
[15] A. Tall,et al. ATP-Binding Cassette Transporters and HDL Suppress Hematopoietic Stem Cell Proliferation , 2010, Science.
[16] Xuefeng Sun,et al. Lack of independent relationship between age-related kidney function decline and carotid intima-media thickness in a healthy Chinese population. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[17] Jean-Claude Tardif,et al. Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. , 2009, American heart journal.
[18] M. Pencina,et al. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. , 2009, JAMA.
[19] H. Parving,et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. , 2009, The New England journal of medicine.
[20] J. Polak,et al. Cystatin C and carotid intima-media thickness in asymptomatic adults: the Multi-Ethnic Study of Atherosclerosis (MESA). , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[21] T. P. Neufeld,et al. Nutrient-dependent regulation of autophagy through the target of rapamycin pathway. , 2009, Biochemical Society transactions.
[22] F. Burzotta,et al. Cystatin C is associated with an increased coronary atherosclerotic burden and a stable plaque phenotype in patients with ischemic heart disease and normal glomerular filtration rate. , 2008, Atherosclerosis.
[23] T. Simon,et al. Combined Inhibition of CCL2, CX3CR1, and CCR5 Abrogates Ly6Chi and Ly6Clo Monocytosis and Almost Abolishes Atherosclerosis in Hypercholesterolemic Mice , 2008, Circulation.
[24] A. Schlitt,et al. CD14(++)CD16+ monocytes but not total monocyte numbers predict cardiovascular events in dialysis patients. , 2008, Kidney international.
[25] R. Cahill,et al. Prediction of calculated future cardiovascular disease by monocyte count in an asymptomatic population , 2008, Vascular health and risk management.
[26] K. Chow,et al. Carotid intima media thickness predicts cardiovascular diseases in Chinese predialysis patients with chronic kidney disease. , 2007, Journal of the American Society of Nephrology : JASN.
[27] P. Libby,et al. Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. , 2007, The Journal of clinical investigation.
[28] E. Kang,et al. The association of total and differential white blood cell count with metabolic syndrome in type 2 diabetic patients. , 2006, Diabetes research and clinical practice.
[29] B. Kestenbaum,et al. Cystatin C and Prognosis for Cardiovascular and Kidney Outcomes in Elderly Persons without Chronic Kidney Disease , 2006, Annals of Internal Medicine.
[30] W. März,et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. , 2005, The New England journal of medicine.
[31] D. Siscovick,et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. , 2005, The New England journal of medicine.
[32] R. Nelson,et al. Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study. , 2005, Journal of the American Society of Nephrology : JASN.
[33] O. Joakimsen,et al. Monocyte Count Is a Predictor of Novel Plaque Formation: A 7-Year Follow-up Study of 2610 Persons Without Carotid Plaque at Baseline The Tromsø Study , 2005, Stroke.
[34] A. Folsom,et al. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. , 2005, Journal of the American Society of Nephrology : JASN.
[35] Charles E McCulloch,et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.
[36] B. Franklin,et al. Renal dysfunction and acceleration of coronary disease , 2004, Heart.
[37] J. Beilby,et al. Monocyte Count, But Not C-Reactive Protein or Interleukin-6, Is an Independent Risk Marker for Subclinical Carotid Atherosclerosis , 2004, Stroke.
[38] A. Hishida,et al. Impact of carotid atherosclerosis on long-term mortality in chronic hemodialysis patients. , 2003, Kidney international.
[39] N. Day,et al. Smoking status and differential white cell count in men and women in the EPIC-Norfolk population. , 2003, Atherosclerosis.
[40] R. D'Agostino,et al. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. , 2001, JAMA.
[41] G. Berglund,et al. Low-Dose Metoprolol CR/XL and Fluvastatin Slow Progression of Carotid Intima-Media Thickness: Main Results From the &bgr;-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS) , 2001, Circulation.
[42] A. Levey,et al. A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.
[43] J. Scherberich,et al. Expanded CD14+ CD16+Monocyte Subpopulation in Patients with Acute and Chronic Infections Undergoing Hemodialysis , 1998, Infection and Immunity.
[44] G. Pacini,et al. Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. , 1998, Kidney international.
[45] C. Kahn,et al. Bidirectional modulation of insulin action by amino acids. , 1998, The Journal of clinical investigation.
[46] P. D. de Feyter,et al. Atherosclerotic changes in the carotid artery bulb as measured by B-mode ultrasound are associated with the extent of coronary atherosclerosis. , 1997, Stroke.
[47] P. Nestel,et al. Increased lipoprotein-remnant formation in chronic renal failure. , 1982, The New England journal of medicine.
[48] G. Miller,et al. PLASMA-HIGH-DENSITY-LIPOPROTEIN CONCENTRATION AND DEVELOPMENT OF ISCHÆMIC HEART-DISEASE , 1975, The Lancet.
[49] P. P. Toth. Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy , 2012 .
[50] D. Fliser,et al. CD14++CD16+ monocytes and cardiovascular outcome in patients with chronic kidney disease. , 2011, European heart journal.
[51] B. Astor,et al. Lipoprotein abnormalities associated with mild impairment of kidney function in the multi-ethnic study of atherosclerosis. , 2008, Clinical journal of the American Society of Nephrology : CJASN.
[52] E. Bonora,et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. , 2000, Diabetes care.